Current siRNA Targets in the prevention and treatment of intimal hyperplasia

Discovery Medicine

Volumn 18, Issue 98, 2014, Pages 125-132

  Pradhan Nabzdyk, Leena ^a   Huang, Chenyu ^a   LoGerfo, Frank W ^a   Nabzdyk, Christoph S ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOGRAFT INFLAMMATORY FACTOR 1; ANGIOTENSIN II; CADHERIN; CAVEOLIN 1; CHEMOKINE RECEPTOR CXCR4; CHLORIDE CHANNEL; CONNECTIVE TISSUE GROWTH FACTOR; CONNEXIN 43; CYCLIN D1; EPIDERMAL GROWTH FACTOR RECEPTOR; GAMMA INTERFERON INDUCIBLE PROTEIN 10; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MARCKS PROTEIN; MATRIX METALLOPROTEINASE 14; MIDKINE; PROTEIN KINASE C DELTA; PROTEIN PATCHED 1; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 1; SMALL INTERFERING RNA; SODIUM CHANNEL NAV1.7; SOMATOMEDIN C; SONIC HEDGEHOG PROTEIN; SURVIVIN; THROMBOSPONDIN 2; TOLL LIKE RECEPTOR 4; TRANSCRIPTION FACTOR AP 1; TRANSCRIPTION FACTOR E2F; TRANSCRIPTION FACTOR GLI2; TRANSFORMING GROWTH FACTOR BETA1; UNINDEXED DRUG; AUTACOID; CELL CYCLE PROTEIN; GROWTH INHIBITOR; GROWTH PROMOTOR; MEMBRANE PROTEIN; PEPTIDE HYDROLASE; PROTEIN KINASE C; PROTEINASE INHIBITOR; TRANSCRIPTION FACTOR;

ANTISENSE THERAPY; AORTA ANEURYSM; ARTERY INTIMA PROLIFERATION; ARTICLE; ATHEROSCLEROSIS; CELL PROLIFERATION; CLINICAL TRIAL (TOPIC); GENE SILENCING; GRAFT FAILURE; HUMAN; MOLECULARLY TARGETED THERAPY; NONHUMAN; ONCOGENE C MYC; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; VASCULAR REMODELING; VEIN GRAFT; ADVERSE EFFECTS; ANGIOPLASTY; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD VESSEL TRANSPLANTATION; CORONARY ARTERY BYPASS GRAFT; GENETICS; HYPERPLASIA; INTIMA; PATHOLOGY;

ANGIOPLASTY; ANIMALS; BLOOD VESSEL PROSTHESIS IMPLANTATION; CELL CYCLE PROTEINS; CORONARY ARTERY BYPASS; GROWTH INHIBITORS; GROWTH SUBSTANCES; HUMANS; HYPERPLASIA; INFLAMMATION MEDIATORS; MEMBRANE PROTEINS; PEPTIDE HYDROLASES; PROTEASE INHIBITORS; PROTEIN KINASE C; RNA, SMALL INTERFERING; TRANSCRIPTION FACTORS; TUNICA INTIMA;

EID: 84940496974     PISSN: 15396509     EISSN: 19447930     Source Type: Journal    
DOI: None     Document Type: Article

References (57)

1. Bai X, Margariti A, Hu Y, Sato Y, Zeng L, Ivetic A, Habi O, Mason JC, Wang X, Xu Q. Protein kinase C{delta} deficiency accelerates neointimal lesions of mouse injured artery involving delayed reendothelialization and vasohibin-1 accumulation. Arterioscler Thromb Vasc Biol 30(12):2467-2474, 2010.
2. Bakken AM, Protack CD, Roztocil E, Nicholl SM, Davies MG. Cell migration in response to the amino-terminal fragment of urokinase requires epidermal growth factor receptor activation through an ADAM-mediated mechanism. J Vasc Surg 49(5):1296-1303, 2009.
3. Bangalore S, Kumar S, Fusaro M, Amoroso N, Attubato MJ, Feit F, Bhatt DL, Slater J. Short- and long-term outcomes with drug-eluting and bare-metal coronary stents: a mixed-treatment comparison analysis of 117 762 patient-years of follow-up from randomized trials. Circulation 125(23):2873-2891, 2012.
4. Banno H, Takei Y, Muramatsu T, Komori K, Kadomatsu K. Controlled release of small interfering RNA targeting midkine attenuates intimal hyperplasia in vein grafts. J Vasc Surg 44(3):633-641, 2006.
5. Bhasin M, Huang Z, Pradhan-Nabzdyk L, Malek JY, Logerfo PJ, Contreras M, Guthrie P, Csizmadia E, Andersen N, Kocher O, Ferran C, Logerfo FW. Temporal network based analysis of cell specific vein graft transcriptome defines key pathways and hub genes in implantation injury. PLoS One 7(6):e39123, 2012.
6. Cheng G, Kim MJ, Jia G, Agrawal DK. Involvement of chloride channels in IGF-I-induced proliferation of porcine arterial smooth muscle cells. Cardiovasc Res 73(1):198-207, 2007.
7. Coelho T, Adams D, Silva A, Lozeron P, Hawkins PN, Mant T, Perez J, Chiesa J, Warrington S, Tranter E, Munisamy M, Falzone R, Harrop J, Cehelsky J, Bettencourt BR, Geissler M, Butler JS, Sehgal A, Meyers RE, Chen Q, et al. Safety and efficacy of RNAi therapy for transthyretin amyloidosis. N Engl J Med 369(9):819-829, 2013.
8. Conte MS, Bandyk DF, Clowes AW, Moneta GL, Seely L, Lorenz TJ, Namini H, Hamdan AD, Roddy SP, Belkin M, Berceli SA, Demasi RJ, Samson RH, Berman SS, Investigators PI. Results of PREVENT III: a multicenter, randomized trial of edifoligide for the prevention of vein graft failure in lower extremity bypass surgery. J Vasc Surg 43(4):742-751; discussion 751, 2006.
9. Davies MG, Hagen PO. Pathobiology of intimal hyperplasia. Br J Surg 81(9):1254-1269, 1994.
10. Dorsett Y, Tuschl T. siRNAs: applications in functional genomics and potential as therapeutics. Nat Rev Drug Discov 3(4):318-329, 2004.
11. Duru EA, Fu Y, Davies MG. Urokinase requires NAD(P)H oxidase to transactivate the epidermal growth factor receptor. Surgery 152(5):879-885, 2012.
12. El-Hayek G, Messerli F, Bangalore S, Hong MK, Herzog E, Benjo A, Tamis-Holland JE. Meta-Analysis of Randomized Clinical Trials Comparing Short-Term Versus Long-Term Dual Antiplatelet Therapy Following Drug-Eluting Stents. Am J Cardiol 114(2):236-242, 2014.
13. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411(6836):494-498, 2001.
14. Geisterfer AA, Peach MJ, Owens GK. Angiotensin II induces hypertrophy, not hyperplasia, of cultured rat aortic smooth muscle cells. Circ Res 62(4):749-756, 1988.
15. Giangrande PH, Zhang J, Tanner A, Eckhart AD, Rempel RE, Andrechek ER, Layzer JM, Keys JR, Hagen PO, Nevins JR, Koch WJ, Sullenger BA. Distinct roles of E2F proteins in vascular smooth muscle cell proliferation and intimal hyperplasia. Proc Natl Acad Sci U S A 104(32):12988-12993, 2007.
16. Goel SA, Guo LW, Liu B, Kent KC. Mechanisms of post-intervention arterial remodelling. Cardiovasc Res 96(3):363-371, 2012.
17. Hlawaty H, Jacob MP, Louedec L, Letourneur D, Brink C, Michel JB, Feldman L, Back M. Leukotriene receptor antagonism and the prevention of extracellular matrix degradation during atherosclerosis and in-stent stenosis. Arterioscler Thromb Vasc Biol 29(4):518-524, 2009.
18. Jia G, Aggarwal A, Yohannes A, Gangahar DM, Agrawal DK. Cross-talk between angiotensin II and IGF-1-induced connexin 43 expression in human saphenous vein smooth muscle cells. J Cell Mol Med 15(8):1695-1702, 2011.
19. Jia G, Cheng G, Gangahar DM, Agrawal DK. Involvement of connexin 43 in angiotensin II-induced migration and proliferation of saphenous vein smooth muscle cells via the MAPK-AP-1 signaling pathway. J Mol Cell Cardiol 44(5):882-890, 2008.
20. Karper JC, De Vries MR, Van Den Brand BT, Hoefer IE, Fischer JW, Jukema JW, Niessen HW, Quax PH. Toll-like receptor 4 is involved in human and mouse vein graft remodeling, and local gene silencing reduces vein graft disease in hypercholesterolemic APOE*3Leiden mice. Arterioscler Thromb Vasc Biol 31(5):1033-1040, 2011.
21. Kundi R, Hollenbeck ST, Yamanouchi D, Herman BC, Edlin R, Ryer EJ, Wang C, Tsai S, Liu B, Kent KC. Arterial gene transfer of the TGF-beta signalling protein Smad3 induces adaptive remodelling following angioplasty: a role for CTGF. Cardiovasc Res 84(2):326-335, 2009.
22. Li F, Duman-Scheel M, Yang D, Du W, Zhang J, Zhao C, Qin L, Xin S. Sonic hedgehog signaling induces vascular smooth muscle cell proliferation via induction of the G1 cyclin-retinoblastoma axis. Arterioscler Thromb Vasc Biol 30(9):1787-1794, 2010.
23. Lingel A, Simon B, Izaurralde E, Sattler M. Structure and nucleic-acid binding of the Drosophila Argonaute 2 PAZ domain. Nature 426(6965):465-469, 2003.
24. Liu X, Luo F, Pan K, Wu W, Chen H. High glucose upregulates connective tissue growth factor expression in human vascular smooth muscle cells. BMC Cell Biol 8:1, 2007.
25. Loh JP, Torguson R, Pendyala LK, Omar A, Chen F, Satler LF, Pichard AD, Waksman R. Impact of early versus late clopidogrel discontinuation on stent thrombosis following percutaneous coronary intervention with first- and second-generation drug-eluting stents. Am J Cardiol 113(12):1968-1976, 2014.
26. Luo DX, Cheng J, Xiong Y, Li J, Xia C, Xu C, Wang C, Zhu B, Hu Z, Liao DF. Static pressure drives proliferation of vascular smooth muscle cells via caveolin-1/ERK1/2 pathway. Biochem Biophys Res Commun 391(4):1693-1697, 2010.
27. Ma Z, Wang H, Wu L, Zhui L, Shi W, Ma D, Chen Z, Yu B. RNAi-mediated Rab5a suppression inhibits proliferation and migration of vascular smooth muscle cells. Acta Cardiol 65(5):507-514, 2010.
28. Meguro K, Iida H, Takano H, Morita T, Sata M, Nagai R, Nakajima T. Function and role of voltage-gated sodium channel NaV1.7 expressed in aortic smooth muscle cells. Am J Physiol Heart Circ Physiol 296(1):H211-H219, 2009.
29. Meng XB, Bi XL, Zhao HL, Feng JB, Zhang JP, Song GM, Sun WY, Bi YW. Small interfering RNA targeting nuclear factor kappa B to prevent vein graft stenosis in rat models. Transplant Proc 45(6):2553-2558, 2013.
30. Miyachi H, Mii S, Enomoto A, Murakumo Y, Kato T, Asai N, Komori K, Takahashi M. Role of Girdin in intimal hyperplasia in vein grafts and efficacy of atelocollagen-mediated application of small interfering RNA for vein graft failure. J Vasc Surg 60(2):479-489.e5, 2013.
31. Monahan TS, Andersen ND, Martin MC, Malek JY, Shrikhande GV, Pradhan L, Ferran C, Logerfo FW. MARCKS silencing differentially affects human vascular smooth muscle and endothelial cell phenotypes to inhibit neointimal hyperplasia in saphenous vein. FASEB J 23(2):557-564, 2009.
32. Monahan TS, Andersen ND, Panossian H, Kalish JA, Daniel S, Shrikhande GV, Ferran C, Logerfo FW. A novel function for cadherin 11/osteoblast-cadherin in vascular smooth muscle cells: modulation of cell migration and proliferation. J Vasc Surg 45(3):581-589, 2007.
33. Mountain DJ, Kirkpatrick SS, Freeman MB, Stevens SL, Goldman MH, Grandas OH. Role of MT1-MMP in estrogen-mediated cellular processes of intimal hyperplasia. J Surg Res 173(2):224-231, 2012.
34. Nabzdyk CS, Chun MC, Oliver-Allen HS, Pathan SG, Phaneuf MD, You JO, Pradhan-Nabzdyk LK, Logerfo FW. Gene silencing in human aortic smooth muscle cells induced by PEI-siRNA complexes released from dip-coated electrospun poly(ethylene terephthalate) grafts. Biomaterials 35(9):3071-3079, 2014.
35. Nabzdyk CS, Lancero H, Nguyen KP, Salek S, Conte MS. RNA interference-mediated survivin gene knockdown induces growth arrest and reduced migration of vascular smooth muscle cells. Am J Physiol Heart Circ Physiol 301(5):H1841-H1849, 2011.
36. Panchenko MP, Siddiquee Z, Dombkowski DM, Alekseyev YO, Lenburg ME, Walker JD, Macgillivray TE, Preffer FI, Stone JR. Protein kinase CK1alphaLS promotes vascular cell proliferation and intimal hyperplasia. Am J Pathol 177(3):1562-1572, 2010.
37. Pradhan-Nabzdyk L, Huang C, Logerfo FW, Nabzdyk CS. Current siRNA targets in atherosclerosis and aortic aneurysm. Discov Med 17(95):233-246, 2014.
38. Pullmann R, Jr., Juhaszova M, Lopez De Silanes I, Kawai T, Mazan-Mamczarz K, Halushka MK, Gorospe M. Enhanced proliferation of cultured human vascular smooth muscle cells linked to increased function of RNA-binding protein HuR. J Biol Chem 280(24):22819-22826, 2005.
39. Redmond EM, Hamm K, Cullen JP, Hatch E, Cahill PA, Morrow D. Inhibition of patched-1 prevents injury-induced neointimal hyperplasia. Arterioscler Thromb Vasc Biol 33(8):1960-1964, 2013.
40. Sommerville LJ, Xing C, Kelemen SE, Eguchi S, Autieri MV. Inhibition of allograft inflammatory factor-1 expression reduces development of neointimal hyperplasia and p38 kinase activity. Cardiovasc Res 81(1):206-215, 2009.
41. Sun DX, Liu Z, Tan XD, Cui DX, Wang BS, Dai XW. Nanoparticle-mediated local delivery of an antisense TGF-beta1 construct inhibits intimal hyperplasia in autogenous vein grafts in rats. PLoS One 7(7):e41857, 2012.
42. Suwanabol PA, Seedial SM, Shi X, Zhang F, Yamanouchi D, Roenneburg D, Liu B, Kent KC. Transforming growth factor-beta increases vascular smooth muscle cell proliferation through the Smad3 and extracellular signal-regulated kinase mitogen-activated protein kinases pathways. J Vasc Surg 56(2):446-454, 2012a.
43. Suwanabol PA, Seedial SM, Zhang F, Shi X, Si Y, Liu B, Kent KC. TGF-beta and Smad3 modulate PI3K/Akt signaling pathway in vascular smooth muscle cells. Am J Physiol Heart Circ Physiol 302(11):H2211-H2219, 2012b.
44. Tabernero J, Shapiro GI, Lorusso PM, Cervantes A, Schwartz GK, Weiss GJ, Paz-Ares L, Cho DC, Infante JR, Alsina M, Gounder MM, Falzone R, Harrop J, White AC, Toudjarska I, Bumcrot D, Meyers RE, Hinkle G, Svrzikapa N, Hutabarat RM, et al. First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement. Cancer Discov 3(4):406-417, 2013.
45. Tsai S, Hollenbeck ST, Ryer EJ, Edlin R, Yamanouchi D, Kundi R, Wang C, Liu B, Kent KC. TGF-beta through Smad3 signaling stimulates vascular smooth muscle cell proliferation and neointimal formation. Am J Physiol Heart Circ Physiol 297(2):H540-H549, 2009.
46. Turner NA, Hall KT, Ball SG, Porter KE. Selective gene silencing of either MMP-2 or MMP-9 inhibits invasion of human saphenous vein smooth muscle cells. Atherosclerosis 193(1):36-43, 2007.
47. Varcoe RL, Mikhail M, Guiffre AK, Pennings G, Vicaretti M, Hawthorne WJ, Fletcher JP, Medbury HJ. The role of the fibrocyte in intimal hyperplasia. J Thromb Haemost 4(5):1125-1133, 2006.
48. Wallitt EJ, Jevon M, Hornick PI. Therapeutics of vein graft intimal hyperplasia: 100 years on. Ann Thorac Surg 84(1):317-323, 2007.
49. Wang J, Liu K, Shen L, Wu H, Jing H. Small interfering RNA to c-myc inhibits vein graft restenosis in a rat vein graft model. J Surg Res 169(1):e85-e91, 2011.
50. Wang L, Zheng J, Bai X, Liu B, Liu CJ, Xu Q, Zhu Y, Wang N, Kong W, Wang X. ADAMTS-7 mediates vascular smooth muscle cell migration and neointima formation in balloon-injured rat arteries. Circ Res 104(5):688-698, 2009.
51. Yokote K, Take A, Nakaseko C, Kobayashi K, Fujimoto M, Kawamura H, Maezawa Y, Nishimura M, Mori S, Saito Y. Bone marrow-derived vascular cells in response to injury. J Atheroscler Thromb 10(4):205-210, 2003.
52. Yoshida S, Nabzdyk CS, Pradhan L, Logerfo FW. Thrombospondin-2 gene silencing in human aortic smooth muscle cells improves cell attachment. J Am Coll Surg 213(5):668-676, 2011.
53. Zamore PD, Tuschl T, Sharp PA, Bartel DP. RNAi: double-stranded RNA directs the ATP-dependent cleavage of mRNA at 21 to 23 nucleotide intervals. Cell 101(1):25-33, 2000.
54. Zhang HW, Zhang T, Shen BZ, Liu M, Liu JR. Toxicological insight from AP-1 silencing study on proliferation, migration, and dedifferentiation of rat vascular smooth muscle cell. Cardiovasc Toxicol 12(1):25-38, 2012.
55. Zhang LL, Gao CY, Fang CQ, Wang YJ, Gao D, Yao GE, Xiang J, Wang JZ, Li JC. PPARgamma attenuates intimal hyperplasia by inhibiting TLR4-mediated inflammation in vascular smooth muscle cells. Cardiovasc Res 92(3):484-493, 2011.
56. Zou Y, Fu Y, Davies MG. Galphaq G proteins modulate MMP-9 gelatinase during remodeling of the murine femoral artery. J Surg Res 181(1):32-40, 2013.
57. Zuojun H, Lingyu H, Wei H, Henghui Y, Chonggang Z, Jingsong W, Mian W, Yong L, Shenming W. Interference of IP-10 expression inhibits vascular smooth muscle cell proliferation and intimal hyperplasia in carotid artery: a new insight in the prevention of restenosis. Cell Biochem Biophys 62(1):125-135, 2012.